Literature DB >> 16173019

Characterization of the homo- and heterotypic immune responses after natural norovirus infection.

Barry Rockx1, Ralph S Baric, Ingrid de Grijs, Erwin Duizer, Marion P G Koopmans.   

Abstract

Noroviruses (NoV) are a genetically and antigenically diverse group of viruses that are common causes of outbreaks of gastroenteritis in humans of all ages. Limited information has been obtained on type specificity of the NoV immune response. In this study, we characterized the homologous and heterologous antibody responses in adults from 13 outbreaks, representing 4 different NoV genotypes. NoV specific IgG and IgA antibodies were determined as well as the increase of antibody avidity. In addition, antibody-mediated blocking of NoV binding to its putative receptor was evaluated. Both homologous and heterologous serological responses were detected after NoV infection. The avidity of antibodies could not be used to distinguish between homologous and heterologous antibody responses. However, a homologous blocking response but not a heterologous response was detected after infection with NoV belonging to genogroup II.4 by a NoV ligand binding inhibition assay. Infection with NoV induces antibodies that can block virus ligand interactions. In contrast with all currently known antibody detection assays for NoV, this can be used as a type specific assay and may be an alternative for studying neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173019     DOI: 10.1002/jmv.20473

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  25 in total

Review 1.  Murine norovirus: a model system to study norovirus biology and pathogenesis.

Authors:  Christiane E Wobus; Larissa B Thackray; Herbert W Virgin
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Model systems for the study of human norovirus Biology.

Authors:  S Vashist; D Bailey; A Putics; I Goodfellow
Journal:  Future Virol       Date:  2009-07       Impact factor: 1.831

Review 3.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

4.  Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner.

Authors:  Stefan Taube; Jeffrey W Perry; Eoghan McGreevy; Kristen Yetming; Cheryl Perkins; Kenneth Henderson; Christiane E Wobus
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

5.  Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Authors:  Jacob Kocher; Tammy Bui; Ernawati Giri-Rachman; Ke Wen; Guohua Li; Xingdong Yang; Fangning Liu; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Authors:  Jackie E Mahar; Nicole C Donker; Karin Bok; Gert H Talbo; Kim Y Green; Carl D Kirkwood
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

8.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles.

Authors:  L Huhti; V Blazevic; K Nurminen; T Koho; V P Hytönen; T Vesikari
Journal:  Arch Virol       Date:  2010-08-19       Impact factor: 2.574

Review 10.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.